RECOMBINANT CANCER THERAPEUTIC CYTOKINE

    公开(公告)号:US20210147502A1

    公开(公告)日:2021-05-20

    申请号:US17082523

    申请日:2020-10-28

    Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

    Guidewire retention clip
    36.
    发明授权

    公开(公告)号:US10980984B2

    公开(公告)日:2021-04-20

    申请号:US15955738

    申请日:2018-04-18

    Abstract: A guidewire retention clip is provided to prevent the accidental, complete insertion of a guidewire into a patient during various procedures. As provided herein, the guidewire retention clip may include a body having a portion configured to hold a guidewire; a sensor associated with the body configured to detect movement of the guidewire to and from the body; and an audio and/or visual indicator arranged on the body, wherein the audio and/or visual indicator is triggered when the sensor detects movement of the guidewire. Methods of using the guidewire retention clip are also provided.

    OmpA and Asp14 in vaccine compositions and as diagnostic targets

    公开(公告)号:US10736951B2

    公开(公告)日:2020-08-11

    申请号:US16454797

    申请日:2019-06-27

    Inventor: Jason A. Carlyon

    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

Patent Agency Ranking